TIAN RUIXIANG Unveils unprecedented Asia-Pacific AI Healthcare Revolution: Strategic Partnership & Acquisition of Singapore’s Top 3 Medical Leaders to Dominate AI-Driven Diagnostics Across Southeast Asia

Rhea-AI Summary

Tian Ruixiang Holdings (NASDAQ: TIRX) announced strategic partnership and acquisition discussions with Singapore’s top three medical technology leaders, aiming to complete transactions within 12 months. The plan integrates proprietary AI diagnostics into a pan‑Asia insurance‑clinic network, targeting 95%+ diagnostic accuracy, automating 70% of routine workflows, and reducing operational costs by 40%+.

The transactions are subject to customary closing conditions, including regulatory approvals and shareholder consent, and include no disclosed deal values.

Positive

• Planned acquisition and partnership with Singapore’s top three medical tech leaders within 12 months
• Targeting 95%+ diagnostic accuracy via integrated AI platforms
• Aiming to automate 70% of routine healthcare workflows
• Projected operational cost reduction of 40%+ across clinics

Negative

• Transactions are contingent on regulatory approvals and shareholder consent
• No transaction values or binding contracts disclosed for the acquisitions
• All performance claims are forward‑looking and dependent on successful integration

News Market Reaction – TIRX

-4.35%

23 alerts

-4.35% News Effect

-36.1% Trough in 38 hr 59 min

-$505K Valuation Impact

$11M Market Cap

0.1x Rel. Volume

On the day this news was published, TIRX declined 4.35%, reflecting a moderate negative market reaction. Argus tracked a trough of -36.1% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $505K from the company's valuation, bringing the market cap to $11M at that time.

Data tracked by StockTitan Argus on the day of publication.

Beijing/Singapore, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Tian Ruixiang Holdings Limited ("Tianruixiang" or the "Company") (NASDAQ: TIRX), a global trailblazer in AI-powered insurance innovation, today announced a landmark expansion of its transformative ecosystem, cementing its position as the undisputed leader in AI-driven healthcare across Southeast Asia and the Asia-Pacific. Building on its historic AI initiative with top-tier global insurance firms, TIRX has entered into strategic partnership and acquisition discussions with Singapore’s top three medical technology leaders, a move set to redefine the future of insurance-clinic integration and precision diagnostics in the region.

The proposed collaboration and acquisitions, which are expected to be finalized within the next 12 months, will integrate Singapore’s world-renowned AI diagnostic expertise directly into TIRX’s expanding pan-Asia network. This strategic fusion will create a fully integrated AI healthcare platform, delivering unparalleled precision, accessibility, and efficiency for patients, providers, and insurers across Southeast Asia and the broader Asia-Pacific.

A Paradigm Shift in Regional Healthcare

"Following our historic redefinition of the insurance industry, we are now igniting a healthcare revolution across the Asia-Pacific," declared the CEO of Tian Ruixiang Holdings Limited. "Singapore’s medical technology sector is the global gold standard for innovation and precision. By integrating its top three leaders into our AI ecosystem, we are not just expanding our footprint—we are building a new era of AI-driven healthcare where diagnostics are proactive, personalized, and seamlessly integrated into every patient’s insurance journey."

The strategic partnership will focus on three transformative pillars:

- AI Diagnostic Supremacy: Leveraging Singaporean medical tech leaders’ proprietary AI platforms to deliver 95%+ accurate predictive diagnostics directly within TIRX’s insurance clinic networks, revolutionizing early disease detection and treatment outcomes.

- Pan-Asia Integration: Establishing a seamless Asia-Pacific network of insurance clinics powered by TIRX’s AI infrastructure, enabling real-time patient data integration, genomic sequencing analysis, and personalized treatment pathways across borders.

- Operational Excellence: Automating 70% of routine healthcare workflows, reducing operational costs by over 40%, and unlocking trillions in latent value across the healthcare value chain.

"Asia-Pacific is the epicenter of global healthcare growth, and AI is the key to unlocking its full potential," added the CTO of TIRX. "By combining our insurance AI leadership with Singapore’s medical tech dominance, we are creating a blueprint for the future—one that is proactive, personalized, and accessible to all."

Accelerated Growth & Market Leadership

The completion of the proposed acquisitions and strategic partnership is subject to customary closing conditions, including regulatory approvals and shareholder consent. TIRX expects to finalize all details and complete the transactions within the next 12 months, positioning the company as the dominant player in the Asia-Pacific AI healthcare market and a catalyst for exponential growth in AI-related revenue.

"Today, we cross the threshold from insurance innovation to healthcare leadership," concluded the CEO. "TIRX is not just a stock—it’s a ticket to the future of healthcare in the world’s most dynamic region. For patients, partners, and investors, the revolution starts now."

About Tian Ruixiang Holdings Limited
Tian Ruixiang Holdings Limited (NASDAQ: TIRX) is a global leader in AI-powered insurance and healthcare innovation. The company’s transformative AI ecosystem is designed to redefine productivity, unlock trillions in latent value, and render legacy business operations obsolete across the insurance and healthcare industries. For more information, visit [www.tianruixiang.com].

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

For investor and media enquiries, please contact:

TIAN RUIXIANG Holdings Ltd
Investor Relations Department
Email: ir@tianrx.com

FAQ

What acquisitions did Tian Ruixiang (TIRX) announce on February 12, 2026?

Tian Ruixiang announced talks to acquire and partner with Singapore’s top three medical tech leaders to integrate AI diagnostics. According to the company, the deals aim to fold Singaporean AI expertise into TIRX’s pan‑Asia insurance‑clinic network and are expected to complete within 12 months.

What diagnostic accuracy does TIRX claim for its AI healthcare platform (TIRX)?

TIRX claims its integrated AI diagnostics will deliver over 95% predictive accuracy for diagnostics across its network. According to the company, this figure reflects proprietary Singaporean AI platforms combined with TIRX’s insurance clinic data for earlier disease detection.

How will the proposed TIRX acquisitions affect operational efficiency and costs?

TIRX says the integration will automate 70% of routine healthcare workflows and cut operational costs by more than 40%. According to the company, automation and AI efficiencies are expected to unlock substantial latent value across the healthcare value chain.

When will the TIRX strategic partnership and acquisitions be completed?

TIRX expects to finalize the partnership and acquisitions within the next 12 months, subject to closing conditions. According to the company, customary regulatory approvals and shareholder consent are required before completion.

Are there disclosed financial terms or guarantees for the TIRX–Singapore deals (TIRX)?

No specific deal values or binding financial terms were disclosed in the announcement. According to the company, details remain subject to final agreements, regulatory approvals, and shareholder consent prior to closing.